



Ian Cooper's
Speed Retirement System

Inside the New Technologies Revolution

Special Report
Summer 2013

Arch Therapeutics (ARTH) to debut what may be the most important medical discovery in decades.



Their newly developed product, AC5™, "heals" a bleeding wound in seconds! This is a breakthrough product that can radically impact bleeding control in surgery, trauma care, even your child's scraped knee!

All totaled:

Arch Therapeutics (ARTH) is set to totally disrupt a \$32 billion global market that hasn't seen a major breakthrough in decades.

You can expect that when this news reaches broad markets, ARTH shares could soar 300% to 500% almost immediately!



Fellow Investor:

For decades, bleeding complications have been a major problem in surgery, often triggering life-threatening nightmares for surgeons, doctors and patients.

That's not all.

Bleeding control is essential trauma response, especially in the military where it is the number one cause of death on the battlefield.

Even at home, bleeding control from scrapes and cuts depends on a 100-year old approach that may soon be obsolete.

This breakthrough product from **Arch Therapeutics (ARTH)** could be worth a fortune to you, if you act immediately. Here's why.



BUY ALERT!

ARCH
THERAPEUTICS

Company: **Arch Therapeutics**
Symbol: **OTCQB: ARTH**
Initial offering: **\$1.00**
Early Growth: **\$3.00**
Long Term: **\$20+ on global roll-out or IP acquisition**

Get Your FREE REPORT ▶

Arch Therapeutics is preparing its breakthrough bleeding control product, AC5™, for final phases to market... and I'm strongly recommending ARTH as an immediate buy.

This may be your last chance to catch ARTH early.

The profit potential in **ARTH** today is simply enormous. If you're excited about catching a breakout early, you'll want to read my new online report right now. It reveals details how:

- ✓ **Arch Therapeutics gained exclusive licenses to the product from the Massachusetts Institute of Technology.....**
- ✓ **Pre-clinical trials confirmed its efficacy with stunning results...**
- ✓ **It is now entering human trials to regulatory approval, which is the pivotal point for ground floor investing...**
- ✓ **A stellar team of world-renown medical researchers, surgeons and medical products specialists are preparing to bring this product to market...**

- ✓ Surgeons are already calling this the "Holy Grail" that could be used in "80% of cases"...
- ✓ Its European introduction should accelerate regulatory approvals to explosive growth in America...

And most important for investors...

This is the **entry point** where **ARTH remains off-radar**, unknown to even seasoned biotech investors!

But with final phases of product trials and approvals underway, **this won't last long!**

A buy now in ARTH can put you weeks ahead of a rush that could rapidly triple, even quintuple ARTH into the \$3.00 to \$5.00 range this year.

Yes, that means you can still own ARTH shares for around a dollar!

Don't expect that to last.

Arch Therapeutics clearly qualifies as one of the best medical technology stocks I've uncovered in my career. The product is a genuine breakthrough, its uses are global, and the profit potential for shareholders is stunning.

You can get all the details on this emerging story through my new report. I urge you to read it now!

Yours for Profit,



Ian Cooper, Publisher
Speed Retirement System Newsletter

New ARTH Report Available Here

